Halozyme Therapeutics Inc (HALO)

[OncoJock]

Agree that HALO is a gem in many respects, but cannot fathom why share price has suffered so much lately. Seems like only a few months ago, common analyst price targets were in the $55, $60, even $65 range and the way things were going that seemed very doable. The unfavorable patent decision regarding Darzalex Faspro (just one of many co-patented products and then only in Europe) does not seem to justify all the doom and gloom and price pullback of recent weeks and months.

Now, with recent prices mire in the upper 30s and struggling to break above $40, those analysts' price targets seem out of reach. But so little has actually changed with the company itself, especially its long-term forecasts for new revenues stemming from partnerships with some of the largest names in Big Pharma: Roche/Genentech, BMS, JnJ, etc. in some of the fastest-growing and largest therapeutic areas/disease states, namely oncology.

And the company seems to have a marvelous offer to the market, namely, a simple way for makers of immune checkpoint inhibitors (a very competitive, large, and fast-growing market) to gain market share, namely, by easing and speeding the route of administration. Subcutaneous injections, as opposed to intravenous infusions, make the checkpoint inhibitors easier and quicker to administer than competing products.

If all this is true, and there's little meaningful competition, then why or why is the share price languishing so???

-- OJ